Severe acute respiratory syndrome

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device

Friday, June 11, 2021 - 9:10pm

Sofia Q features a sleek, miniaturized design that reads the same Sofia SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy.

Key Points: 
  • Sofia Q features a sleek, miniaturized design that reads the same Sofia SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy.
  • Sales of Sofia Q device will initially be limited to use with the Sofia SARS Antigen FIA in the CLIA and CLIA-waived professional segments.
  • In addition to the Sofia Q, Quidel offers other rapid diagnostic instrumented systems, including Sofia 2, and Sofia.
  • Quidels Sofia assays for rapid antigen COVID-19 diagnosis include Sofia 2 SARS Antigen FIA and Sofia 2 Flu + SARS Antigen FIA, currently under EUA by the FDA.

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

Friday, June 11, 2021 - 12:25pm

Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.

Key Points: 
  • Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.
  • The clinical data for Avactas AffiDX SARS-CoV-2 antigen lateral flow test reported 20 April 2021, demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct
  • The product registration by a Competent Authority in the EU allows the Company to sell the product in the EU for professional use.
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: We are delighted to receive confirmation of the registration of the AffiDX SARS-CoV-2 antigen test in the EU.

NYU Langone Health to Co-Lead NIH-funded Effort to Understand Long-term Effects of SARS-CoV-2 Infection

Thursday, June 10, 2021 - 6:35pm

NEW YORK, June 10, 2021 /PRNewswire/ -- NYU Langone Health has been selected as the Clinical Science Core (CSC) for the National Institutes of Health's PASC (Post-Acute Sequelae of SARS-CoV-2 Infection) Initiative.

Key Points: 
  • NEW YORK, June 10, 2021 /PRNewswire/ -- NYU Langone Health has been selected as the Clinical Science Core (CSC) for the National Institutes of Health's PASC (Post-Acute Sequelae of SARS-CoV-2 Infection) Initiative.
  • Congress provided $1.15 billion in funding over four years for NIH to support research into the prolonged health consequences of SARS-CoV-2 infection in December of 2020.
  • How many people continue to have symptoms of COVID-19, or even develop new symptoms, after acute SARS-CoV-2 infection?
  • The PASC CSC at NYU Langone Health (NIH funding no.

New England Biolabs®, Inc. Launches Primer Monitor Tool for Tracking SARS-CoV-2 Variants That May Impact Primers Used in Diagnostic Assays

Thursday, June 10, 2021 - 6:00pm

The Primer Monitor Tool , which is updated regularly, provides simple visualization of known variants identified in the SARS-CoV-2 genome and offers insight into where commonly used or user-defined primer set assessment may be worthwhile.

Key Points: 
  • The Primer Monitor Tool , which is updated regularly, provides simple visualization of known variants identified in the SARS-CoV-2 genome and offers insight into where commonly used or user-defined primer set assessment may be worthwhile.
  • As the SARS-CoV-2 virus has continued to spread and mutate, concerns have been raised about the effectiveness of current diagnostic tests to detect new strains of the virus.
  • "The tool is pre-loaded with commonly used primer sequences from SARS-CoV-2 qPCR and LAMP assays and ARTIC sequencing workflows (currently v3).
  • NEB and NEW ENGLAND BIOLABS are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/new-england-biolabs-inc-launches...

Xlife Sciences AG: Breakthrough in Drug Development

Thursday, June 10, 2021 - 7:06am

Xlife Sciences AG (XLS DE): Breakthrough in Drug Development First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses.

Key Points: 
  • Xlife Sciences AG (XLS DE): Breakthrough in Drug Development First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses.
  • About Xlife Sciences AG Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry.
  • Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.
  • Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.

Selva Announces SLV213, a Potential Oral COVID-19 Treatment, Has Broad Activity Against SARS-CoV-2 Variants of Concern

Wednesday, June 9, 2021 - 1:00pm

No loss of potency was found and equal activity against all variants was determined, explained Felix Frueh, Ph.D., Chief Scientific Officer of Selva.

Key Points: 
  • No loss of potency was found and equal activity against all variants was determined, explained Felix Frueh, Ph.D., Chief Scientific Officer of Selva.
  • SLV213 has demonstrated activity against SARS-CoV-2 in vitro and in vivo and completed a Phase 1 clinical trial for safety.
  • As an oral antiviral, SLV213 has the potential to fill a critical gap in the treatment landscape for COVID-19.
  • Selva previously reported that SLV213 successfully completed a Phase 1 ascending oral dose clinical trial in healthy subjects.

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Tuesday, June 8, 2021 - 3:31pm

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points: 
  • Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
  • The study was released in preprint via medRXiv.
  • Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
  • Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Tuesday, June 8, 2021 - 3:00pm

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points: 
  • Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
  • The study was released in preprint via medRXiv.
  • Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
  • Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

Thermo Fisher Scientific Launches Ion AmpliSeq SARS-CoV-2 Insight Research Assay for SARS-CoV-2 Surveillance

Monday, June 7, 2021 - 2:00pm

CARLSBAD, Calif., June 7, 2021 /PRNewswire/ --Thermo Fisher Scientific today introduced the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to improve SARS-CoV-2 surveillance.

Key Points: 
  • CARLSBAD, Calif., June 7, 2021 /PRNewswire/ --Thermo Fisher Scientific today introduced the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to improve SARS-CoV-2 surveillance.
  • The new Ion AmpliSeq SARS-CoV-2 Insight Research Assay broadens and improves local, regional and national surveillance efforts to discover emerging SARS-CoV-2 variants through highly sensitive next-generation sequencing (NGS).
  • To further expedite NGS analysis of SARS-CoV-2 and to help meet growing customer demand,Thermo Fisherhas begun optimizing the Ion AmpliSeq SARS-CoV-2 Insight Research Assay for the Ion Torrent Genexus System .
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.

MHRA Confirms Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test

Monday, June 7, 2021 - 8:51am

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that the MHRA has confirmed registration of Avactas AffiDX SARS-CoV-2 antigen lateral flow test allowing the Company to place the product on the market in the UK for professional use.

Key Points: 
  • Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that the MHRA has confirmed registration of Avactas AffiDX SARS-CoV-2 antigen lateral flow test allowing the Company to place the product on the market in the UK for professional use.
  • Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.
  • The clinical data for Avactas AffiDX SARS-CoV-2 antigen lateral flow test reported in April demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: I am delighted to receive confirmation of the registration of the AffiDX SARS-CoV-2 antigen test from the MHRA.